Portfolio, Licensing & Development Strategy
New drug commercial assessment – identifying the best opportunity for phase III investment.
Our client sought to fully understand the market opportunity of their product across 5 widely different potential indications, which spanned from rare nephrology to dermatological conditions.
We quantified this opportunity both scientifically, clinically, and commercially across all indications, to provide a clear business case for the prioritisation of the indications based on overall commercial and clinical opportunity and feasibility.
Share this post
![Testimonial about Portfolio, Licensing & Development Strategy 1 Testimonial about Portfolio, Licensing & Development Strategy 1](https://eradigm.com/wp-content/uploads/2019/04/CaseStudy_Portfolio-Strategy_1-1.jpg)